Author

Ioana Hinshaw

Observed names: I. Hinshaw, Ioana M. Hinshaw

Institution: Rocky Mountain Cancer Centers

Observed institutions: Translational Genomics Research Institute, Norton Healthcare, Nektar Therapeutics (United States), Mayo Clinic Hospital, Rocky Mountain Cancer Centers, Presbyterian St. Luke's Medical Center

OpenAlex ID: A5032564321

A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etirinotecan Pegol in Patients with Refractory Solid Tumors

2012 · Gayle S. Jameson, John T. Hamm, et al. · Clinical Cancer Research · 55

Intraarterial Chemotherapy for Extremity Osteosarcoma and MFH in Adults

2008 · Ronald R. Hugate, Ross M. Wilkins, et al. · Clinical Orthopaedics and Related Research · 31

The Value of Serial Arteriography in Osteosarcoma: Delivery of Chemotherapy, Determination of Therapy Duration, and Prediction of Necrosis

2005 · John W. Cullen, Brandt A. Jamroz, et al. · Journal of Vascular and Interventional Radiology · 24

A Phase Ib/II Study of Cancer Stemness Inhibitor Napabucasin (BB608) Combined with Weekly Paclitaxel in Advanced Triple Negative Breast Cancer.

2016 · Carlos Becerra, Fadi S. Braiteh, et al. · Journal of Clinical Oncology · 13

3436 Efficacy and safety of trabectedin (T) or dacarbazine (D) for treatment of patients (pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) after prior chemotherapy

2015 · G. Demetri, S.R. Patel, et al. · European Journal of Cancer · 1

Works count: 5

Citation count: 124

H-index: 4

I10-index: 4